Tags

Type your tag names separated by a space and hit enter

Effects of simvastatin on carotenoid status in plasma.
Nutr Metab Cardiovasc Dis. 2012 Jan; 22(1):66-71.NM

Abstract

BACKGROUND AND AIMS

Carotenoids are potent antioxidants mainly transported in the low density lipoprotein (LDL) fraction. They may also influence the immune response and inverse associations with inflammatory markers have been reported. We investigated whether simvastatin, by exerting both lipid-lowering and anti-inflammatory effects, altered the carotenoid status in plasma.

METHODS AND RESULTS

A randomized, double-blind, placebo-controlled study design was applied. Eighty volunteers with mild to moderate hypercholesterolemia received either simvastatin 40 mg or placebo for 6 weeks. Lipids, oxidized LDL (ox-LDL), C-reactive protein (CRP), interleukin (IL)-6, oxygenated carotenoids (lutein, zeaxanthin, β-cryptoxanthin) and hydrocarbon carotenoids (α-carotene, β-carotene, lycopene) were measured in plasma. Simvastatin use was associated with significant reductions in total cholesterol, LDL, ox-LDL and CRP. Simvastatin therapy also resulted in reduced plasma levels of both oxygenated and hydrocarbon carotenoids. However, when adjusted for lipids, all carotenoids except β-cryptoxanthin showed significant increases after simvastatin therapy. Both crude and lipid-adjusted carotenoids were inversely correlated with CRP and IL-6 in plasma but the change in carotenoid status during simvastatin therapy was not specifically related to any changes in inflammatory markers.

CONCLUSIONS

To summarize, the change in carotenoid status during simvastatin therapy was mainly attributed to the lowering of cholesterol and not to the suppression of inflammatory activity. After adjustment for lipids, the levels of lutein, lycopene, α-carotene and β-carotene were significantly increased by simvastatin suggesting an increased ratio of carotenoids per particle.

Authors+Show Affiliations

Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, SE-581 85 Linköping, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20678906

Citation

Rydén, M, et al. "Effects of Simvastatin On Carotenoid Status in Plasma." Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, vol. 22, no. 1, 2012, pp. 66-71.
Rydén M, Leanderson P, Kastbom KO, et al. Effects of simvastatin on carotenoid status in plasma. Nutr Metab Cardiovasc Dis. 2012;22(1):66-71.
Rydén, M., Leanderson, P., Kastbom, K. O., & Jonasson, L. (2012). Effects of simvastatin on carotenoid status in plasma. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD, 22(1), 66-71. https://doi.org/10.1016/j.numecd.2010.04.009
Rydén M, et al. Effects of Simvastatin On Carotenoid Status in Plasma. Nutr Metab Cardiovasc Dis. 2012;22(1):66-71. PubMed PMID: 20678906.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of simvastatin on carotenoid status in plasma. AU - Rydén,M, AU - Leanderson,P, AU - Kastbom,K-O, AU - Jonasson,L, Y1 - 2010/08/03/ PY - 2010/02/02/received PY - 2010/04/09/revised PY - 2010/04/13/accepted PY - 2010/8/4/entrez PY - 2010/8/4/pubmed PY - 2012/4/13/medline SP - 66 EP - 71 JF - Nutrition, metabolism, and cardiovascular diseases : NMCD JO - Nutr Metab Cardiovasc Dis VL - 22 IS - 1 N2 - BACKGROUND AND AIMS: Carotenoids are potent antioxidants mainly transported in the low density lipoprotein (LDL) fraction. They may also influence the immune response and inverse associations with inflammatory markers have been reported. We investigated whether simvastatin, by exerting both lipid-lowering and anti-inflammatory effects, altered the carotenoid status in plasma. METHODS AND RESULTS: A randomized, double-blind, placebo-controlled study design was applied. Eighty volunteers with mild to moderate hypercholesterolemia received either simvastatin 40 mg or placebo for 6 weeks. Lipids, oxidized LDL (ox-LDL), C-reactive protein (CRP), interleukin (IL)-6, oxygenated carotenoids (lutein, zeaxanthin, β-cryptoxanthin) and hydrocarbon carotenoids (α-carotene, β-carotene, lycopene) were measured in plasma. Simvastatin use was associated with significant reductions in total cholesterol, LDL, ox-LDL and CRP. Simvastatin therapy also resulted in reduced plasma levels of both oxygenated and hydrocarbon carotenoids. However, when adjusted for lipids, all carotenoids except β-cryptoxanthin showed significant increases after simvastatin therapy. Both crude and lipid-adjusted carotenoids were inversely correlated with CRP and IL-6 in plasma but the change in carotenoid status during simvastatin therapy was not specifically related to any changes in inflammatory markers. CONCLUSIONS: To summarize, the change in carotenoid status during simvastatin therapy was mainly attributed to the lowering of cholesterol and not to the suppression of inflammatory activity. After adjustment for lipids, the levels of lutein, lycopene, α-carotene and β-carotene were significantly increased by simvastatin suggesting an increased ratio of carotenoids per particle. SN - 1590-3729 UR - https://www.unboundmedicine.com/medline/citation/20678906/Effects_of_simvastatin_on_carotenoid_status_in_plasma_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-4753(10)00110-9 DB - PRIME DP - Unbound Medicine ER -